RxDoctor Payments Data

Clifford Poplar, MD

Internal Medicine · Delavan, WINPI 1942396718

Payments from drug & device makers

$664in general payments, 2019–2025

Across 27 payments — averaging $24.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$263
  • Novartis$70
  • E.r. Squibb & Sons, L.L.C.$62
  • Johnson & Johnson$55
  • Novo Nordisk$36
  • Boehringer Ingelheim$35
  • plus $144 from 6 others

What the payments were for

  • Food & beverage$37156%
  • Education$29344%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$664 in reported general payments places this provider in the 85th percentile of 1,411 internal medicine providers in Wisconsin.

See all internal medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$190,118
Medicare patients
409
Services billed
2,693

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban301$253,632
JardianceEmpagliflozin79$86,804
XareltoRivaroxaban114$65,591
JanuviaSitagliptin Phosphate50$50,824
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$35,628
OxycontinOxycodone Hcl28$25,283
FarxigaDapagliflozin Propanediol32$25,040
Breo ElliptaFluticasone/Vilanterol48$22,642
OzempicSemaglutide18$19,607
EntrestoSacubitril/Valsartan23$19,373
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$18,615
MyrbetriqMirabegron16$18,477
MounjaroTirzepatide14$15,629
Lantus SolostarInsulin Glargine,hum.Rec.Anlog124$12,567
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$9,844

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$29$261,976338 claims
Boehringer IngelheimJardiance$35$86,80479 claims
Johnson & JohnsonXarelto$55$65,591114 claims
MerckJanuvia, Janumet Xr$29$56,56563 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$17$38,66155 claims
Novo NordiskOzempic$36$19,60718 claims
NovartisEntresto$70$19,37323 claims
Astellas Pharma US IncMyrbetriq$263$18,47716 claims
Lilly USA, LLCMounjaro$27$15,62914 claims
AbbVieLinzess$30$6,09111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,411 internal medicine providers in Wisconsin.

Other internal medicine in Delavan

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →